


**JAMES D. EASON
TRANSPLANT
INSTITUTE
AT METHODIST
UNIVERSITY
HOSPITAL**



2020 REPORT





LETTER FROM DR. JAMES EASON

Dear Friends,

Despite the challenges presented over the past year due to the COVID-19 public health crisis, the James D. Eason Transplant Institute remained focused on providing comprehensive organ transplantation care to over 270 patients and their families.

Beyond expert clinical care, our team continued to focus on providing holistic care to patients throughout their transplant journey and also expanding access to serve all patients in need, regardless of their circumstances.

The expert physicians on our team have performed more than 5,400 organ transplants since our first kidney transplant in 1970, and we continue to save more lives through liver, kidney, and pancreas transplantation.

We are also proud to continue to be a national-leader and expert in live-donor liver and kidney transplantation.

The beautiful, state-of-the-art transplant facilities within Shorb Tower at Methodist University Hospital afford our staff and patients with a healing, peaceful, and highly functional space that promotes both patient experience and transplant outcomes and serves as a catalyst for innovation in the care we provide.

In collaboration with our academic partner, the University of Tennessee Health Science Center, our Physicians and Clinical Research Faculty at the Transplant Research Institute continue to implement research studies using the latest technology and knowledge to both advance organ transplant outcomes and increase the number of available organs for transplantation.

Serving as a testament to our commitment to this work, our program remained on track in our pursuit of becoming a best-in-class, program of choice for patients in need of organ transplantation. We exceeded the total number of surgeries provided in 2019, providing over 270 transplants in 2020.

We couldn't have gotten to where we are today – in the most advanced and state-of-the-art facility, providing comprehensive organ transplant care to hundreds of patients annually, operating a robust research program, with an expert research and clinical team – without the philanthropy and support of our community, friends, and advocates.

Giving, both in terms of philanthropy and the gift of life and organ donation, continues to transform our Institute into a beacon of hope for those in our community and beyond who need life-saving organ transplantation.

As we look ahead to 2021, we will continue to pursue excellence in the care we provide to our patients and will aggressively push the boundaries of organ transplantation science. Your support makes everything we do possible, and we are most grateful.

Sincerely,

Dr. James D. Eason
Program Director
James D. Eason Transplant Institute at
Methodist University Hospital



2020 IMPACT NUMBERS



119

Adult Liver
Transplants

131

Adult Kidney
Transplants

15

Kidney/Pancreas
Transplants

2

Pediatric Liver
Transplants

5

Pediatric
Kidney
Transplants

214

Pediatric Kidney
Transplants

50+

Years of
Transplantation
Experience

200+

Dedicated Organ
Transplantation
Professionals

* 1/1/20 to 12/31/20

EXTENDING OUR PATIENTS' LIVES

A FATHER & SON'S TRANSPLANT STORY

When Patrick Manning found out his Dad, Mark Manning, needed a liver transplant, he didn't hesitate, "I asked every day, 'When can I call? Who do I need to call?'"

Just months later, Patrick received the call from the team at the James D. Eason Transplant Institute at Methodist University Hospital informing him that he was approved to be his Dad's live liver donor.

He shared, "I felt elated because I could see my Dad walk my sister down the aisle. I would have him in my life. He could enjoy retirement."

In April of 2020, despite the worldwide COVID-19 public health crisis, the Mannings successfully underwent liver transplantation surgery at Methodist University Hospital.

Patrick donated 65% of his healthy liver to Mark, and, within weeks, they both had healthy, regenerated, full-size livers.


Even though they were unable to have their loved ones visit them in the hospital, the two shared that they received immense support from their caregivers and from one another.

The James D. Eason Transplant Institute is among an elite few programs in the United States offering the option of live liver donor transplant surgery.

For patients like Mark who may be on an organ waiting list for years or even pass away before they receive an organ donation, this innovative option is truly life-saving.

Today, Patrick and Mark are both feeling well.

Mark shared, "My recovery was remarkably fast. I feel better now than I did before."



“ I felt elated because I could see my Dad walk my sister down the aisle. I would have him in my life. He could enjoy retirement. ”

- **PATRICK MANNING**
LIVE LIVER DONOR



RESEARCH TO ADVANCE CARE

The James D. Eason Transplant Institute at Methodist University Hospital, in partnership with the University of Tennessee Health Science Center (UTHSC), is dedicated to research in the field of organ transplantation.

With UTHSC, The James D. Eason Transplant Institute operates a Translational Research lab where skilled researchers and Physicians are pursuing excellence in patient experience, clinical quality, and safety, and pushing the boundaries of transplant science through research.

Using both basic and clinical research, our research team, physicians, and faculty are focused on providing cutting-edge transplant therapies and increasing the availability of organs for transplantation as well as long-term organ transplantation patient outcomes.

CURRENT PROJECTS

Advancing Understanding of Ischemia Reperfusion Injury in Liver Donation:
Using RNA sequencing to identify gene expression and miRNA changes, this study seeks to better understand how to address the occurrence of Ischemia Reperfusion Injury in liver donation, storage, and transplantation.

APOL1:
This NIH-funded study established a network of researchers to explore the long-term outcomes of kidney transplantation.

Detecting Organ Quality from Liver Perfusates:
Seeking to better identify quality organs for transplantation, this study is working to identify biomarkers that can classify organ quality using persufate samples from patients with different outcomes and next generation sequencing.

Causation of Focal Segmental GlomeruloSclerosis in Kidney Transplant Patients:
In collaboration with Northwestern University and University of Maryland, this study aims to define reasons for recurrent Focal Segmental GlomeruloSclerosis (FSGS) in kidney transplant patients using genomics, including single-cell and RNA-sequencing.

CMV Specific T-Cell Immune Response Study:
The purpose of this study is to evaluate the CMV specific T-Cell immune response in HCV uninfected renal transplant recipients by comparing transplants from HCV infected and uninfected donors.

Consortium to Study HCV-NAT-Positive Kidney Transplantation:
This collaborative study across research institutions seeks to gain a better understanding of the outcomes of transplanting kidneys from HCV-NAT-positive kidney donors to HCV-negative recipients.

Exploring the Impact of De Novo Hepatitis C Infection in Kidney Transplants:
The purpose of this study is to evaluate the impact of De Novo Hepatitis C infection on dd-cf DNA (AlloSure) in kidney transplant recipients.

Normothermic Liver Perfusion:
This study is exploring the outcomes of using Normothermic ex vivo liver perfusion (NEVLP) for the assessment of allograft function and restoration of intracellular energy stores of livers prior to transplantation.

Mitochondria Therapy - Mitotherapy:
Several studies are underway using rodent trials to investigate the therapeutic use of Mitochondria Therapy for improving healthy liver function in: non-alcoholic fatty liver disease (NAFLD); Ischemia Reperfusion Injury (IRI); and in normothermic ex-vivo perfusion pump to prolong the cold ischemia times.

Mitochondria Therapy to Decrease Ischemia-Reperfusion Injury to Livers:
This collaborative study with Harvard Medical School and Massachusetts General Hospital is examining the effectiveness of mitochondria therapy in decreasing ischemia-reperfusion injury to livers during the transplantation process.

OKRA:
This NIH-funded study is evaluating patient outcomes from kidney care on the renal allografts registry.

INSTITUTE TEAM



As a result of the compelling work taking place through the James D. Eason Transplant Institute and the complex needs of the Memphis and Mid-South community, the program has recruited a stellar team of physicians, caregivers, and research scientists. The Institute employs over 200 Associates who represent the entire spectrum of care. We are proud of our current team that includes the following skilled and dedicated professionals:



The Transplant Institute team is comprised of 200 Methodist Associates who represent every element of the care provided.

TRANSPLANT SURGEONS



Dr. James Eason
Program Director



Dr. Jason Vanatta
Surgical Director of
Liver Transplantation



**Dr. Nosratollah
Nezakatgoo**
Surgical Director of
Pancreas
Transplantation



Dr. Ryan Helmick
Surgical Director of
Kidney Transplantation



Dr. Peter Horton
Transplant Surgeon



Dr. Corey Eymard
Transplant Surgeon

TRANSPLANT HEPATOLOGISTS



Dr. Satheesh Nair
Medical Director of
Liver Transplantation



Dr. Bilal Ali
Transplant
Hepatologist



Dr. Jiten Kothadia
Transplant
Hepatologist

TRANSPLANT NEPHROLOGISTS



Dr. Manish Talwar
Medical Director
of Kidney
Transplantation



**Dr. Vasanthi
Balaraman**
Medical Director of
Live Donor Kidney
Transplantation



Dr. Anshul Bhalla
Transplant
Nephrologist

